


WHAT IS CLAIMED IS:

1. A compound of formula (I) below or a pharmaceutically acceptable salt thereof:



(I),

wherein

R_1 is C_{1-6} alkyl or C_{1-6} thioalkyl;


X is O or NR_a , in which R_a is H or C_{1-6} alkyl;

Y is CR_bR_c or NR_d , in which each of R_b and R_c , independently, is H , halo, C_{1-6} alkyl, C_{1-6} alkoxy, or amino, or R_b , together with R_a , the carbon atom bonded to R_b , and the nitrogen atom bonded to R_a , is C_{3-10} heterocycloalkyl; and R_d is H or C_{1-6} alkyl, or R_d , together with R_a and the nitrogen atoms bonded to R_d and R_a , is C_{3-10} heterocycloalkyl;

R_2 is $-CH_2CH_2R_e$ or NR_fR_g , in which R_e is H , halo, C_{1-6} alkyl, or OR_h and each of R_f and R_g , independently, is C_{1-6} alkyl or C_{3-8} cycloalkyl, R_h being H or C_{1-6} alkyl, or R_h , together with R_d , the oxygen atom bonded to R_h , and the nitrogen atom bonded to R_d , being C_{3-10} heterocycloalkyl; and

R_3 is 6-membered heteroaryl.

2. The compound or salt of claim 1, wherein the compound is of formula (II):



(II),

in which R_1 is C_{1-6} alkyl.

3. The compound or salt of claim 2, wherein X is O, Y is NR_d, and R₂ is –CH₂CH₂R_e, in which R_e is OR_h, R_h, together with R_d, the oxygen atom bonded to R_h, and the nitrogen atom bonded to R_d, being C₃₋₁₀ heterocycloalkyl.

4. The compound or salt of claim 2, wherein X is NR_a and Y is CR_bR_c or NR_d, in which R_a, together with R_b, the nitrogen atom bonded to R_a, and the carbon atom bonded to R_b, is C₃₋₁₀ heterocycloalkyl; R_c is H, halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, or amino; and R_d, together with R_a and the nitrogen atoms bonded to R_a and R_d, is C₃₋₁₀ heterocycloalkyl.

5. The compound or salt of claim 4, wherein X is NR_a, Y is CR_bR_c, and R₂ is NR_fR_g, in which R_a, together with R_b, the nitrogen atom bonded to R_a, and the carbon atom bonded to R_b, is C₃₋₁₀ heterocycloalkyl; R_c is H, halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, or amino; and each of R_f and R_g is C₁₋₆ alkyl.

6. The compound or salt of claim 4, wherein X is NR_a, Y is NR_d, and R₂ is –CH₂CH₂R_e, in which R_a, together with R_d and the nitrogen atoms bonded to R_a and R_d, is C₃₋₁₀ heterocycloalkyl; and R_e is H, halo, or OR_h, R_h being H or C₁₋₆ alkyl.

7. The compound or salt of claim 1, wherein R₃ is 6-membered heteroaryl substituted with one or more (CH₂)_nZ moieties independently, in which n is 0 or 1 and Z is H, halo, CN, OH, CF₃, C₁₋₆ alkyl, or C₁₋₆ alkoxy; or is 6-membered heteroaryl fused with a phenyl ring substituted with one or more substituents independently selected from the group consisting of H, halo, CN, OH, CF₃, C₁₋₆ alkyl, and C₁₋₆ alkoxy.


8. The compound or salt of claim 7, wherein R₃ is 6-membered heteroaryl substituted with one or more (CH₂)_nZ moieties independently, in which n is 0 or 1 and Z is H, halo, CN, OH, CF₃, C₁₋₆ alkyl, or C₁₋₆ alkoxy.

9. The compound or salt of claim 8, wherein R₃ is pyridyl or pyrimidyl.

10. The compound or salt of claim 3, wherein R_3 is 6-membered heteroaryl substituted with one or more $(CH_2)_nZ$ moieties independently, in which n is 0 or 1 and Z is H, halo, CN, OH, CF_3 , C_{1-6} alkyl, or C_{1-6} alkoxy; or is 6-membered heteroaryl fused with a phenyl ring substituted with one or more substituents independently selected from the group consisting of H, halo, CN, OH, CF_3 , C_{1-6} alkyl, and C_{1-6} alkoxy.

11. The compound or salt of claim 10, wherein R_3 is pyridyl or pyrimidyl.


12. The compound or salt of claim 11, wherein the compound is



13. The compound or salt of claim 5, wherein R_3 is 6-membered heteroaryl substituted with one or more $(CH_2)_nZ$ moieties independently, in which n is 0 or 1 and Z is H, halo, CN, OH, CF_3 , C_{1-6} alkyl, or C_{1-6} alkoxy; or is 6-membered heteroaryl fused with a phenyl ring substituted with one or more substituents independently selected from the group consisting of H, halo, CN, OH, CF_3 , C_{1-6} alkyl, and C_{1-6} alkoxy.

14. The compound or salt of claim 13, wherein R_3 is pyridyl or pyrimidyl.


15. The compound or salt of claim 14, wherein the compound is




16. The compound or salt of claim 6, wherein R_3 is 6-membered heteroaryl substituted with one or more $(CH_2)_nZ$ moieties independently, in which n is 0 or 1 and Z is H, halo, CN, OH, CF_3 , C_{1-6} alkyl, or C_{1-6} alkoxy; or is 6-membered heteroaryl fused with a phenyl ring substituted with one or more substituents independently selected from the group consisting of H, halo, CN, OH, CF_3 , C_{1-6} alkyl, and C_{1-6} alkoxy.

17. The compound or salt of claim 16, wherein R_3 is pyridyl or pyrimidyl.


18. The compound or salt of claim 17, wherein the compound is one of the following compounds:



19. The compound or salt of claim 1, wherein the compound is one of the following compounds:



20. The compound or salt of claim 1, wherein the compound is of formula (III):



(III),

in which R₁ is C₁₋₆ alkyl.

21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound or salt of claim 1.

22. A method of inhibiting a tyrosine kinase, comprising contacting the tyrosine kinase with an effective amount of a compound or salt of claim 1.

23. The method of claim 22, wherein the tyrosine kinase is FMS-like tyrosine kinase 3 (FLT3), FMS-like tyrosine kinase 4, vascular endothelial growth factor receptor (VEGFR), colony stimulating factor 1 receptor (CSF1R), platelet-derived growth factor receptor (PDGFR) A, PDGFR B, tyrosine-protein kinase Kit (c-KIT), c-Src (SRC), tyrosine-protein kinase Lyn (LYN) A, LYN B, rearranged during transfection tyrosine kinase (RET), lymphocyte-specific protein tyrosine kinase, Gardner-Rasheed feline sarcoma viral oncogene homolog, discoidin domain receptor 1, kinase insert domain receptor, B lymphocyte kinase, tyrosine-protein kinase Yes, Abelson murine leukemia viral oncogene homolog 1 (ABL1), tyrosine receptor kinase TRKA, TRKB, TRKC, ZAK/MLTK, IRAK4, RET V804L, RET Y791F, FLT3 D835Y, PDGFR A V561D, or ABL1 T315I.

24. The method of claim 23, wherein the tyrosine kinase is FLT3, VEGFR, or c-KIT.

25. The method of claim 24, wherein the cancer is acute myeloid leukemia, chloroma, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, B-cell lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, myelodysplastic syndrome, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, male genital tract cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, uterus cancer, gestational trophoblastic disease, gastric cancer, bile duct cancer, gallbladder cancer, small intestine cancer, esophageal cancer, oropharyngeal cancer, hypopharyngeal cancer, eye cancer, nerve cancer, head and neck cancer, melanoma, plasmacytoma, endocrine gland neoplasm, neuroendocrine cancer, brain tumor, bone cancer, or sarcoma.